Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

First Watch Restaurant Group, Inc. (FWRG) Q3 Earnings Lag Estimates
First Watch Restaurant Group, Inc. (FWRG) Q3 Earnings Lag Estimates

First Watch Restaurant Group, Inc. (FWRG) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.03 per share a

Sotera Health Company (SHC) Q3 Earnings and Revenues Surpass Estimates
Sotera Health Company (SHC) Q3 Earnings and Revenues Surpass Estimates

Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.17 per share a year ago

Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.26 per share a year ago. These

Lindblad Expeditions (LIND) Beats Q3 Earnings and Revenue Estimates
Lindblad Expeditions (LIND) Beats Q3 Earnings and Revenue Estimates

Lindblad Expeditions (LIND) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.22 per share. This compares to earnings of $0.36 per share a year ago

Hillman Solutions Corp. (HLMN) Surpasses Q3 Earnings Estimates
Hillman Solutions Corp. (HLMN) Surpasses Q3 Earnings Estimates

Hillman Solutions Corp. (HLMN) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago

Should You Buy, Hold or Sell ATRO Stock Ahead of Q3 Earnings Release?
Should You Buy, Hold or Sell ATRO Stock Ahead of Q3 Earnings Release?

Astronics Corporation ATRO is slated to release third-quarter 2025 results on Nov. 4, after market close.The Zacks Consensus Estimate for revenues is pegged at $213.3 million, implying 4.7% growth

SM Energy Beats on Q3 Earnings, Announces Merger With Civitas
SM Energy Beats on Q3 Earnings, Announces Merger With Civitas

SM Energy Company SM reported third-quarter 2025 adjusted earnings of $1.33 per share, which surpassed the Zacks Consensus Estimate of $1.25. The bottom line, however, declined from the year-ago

Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates
Neuronetics (STIM) Reports Q3 Loss, Misses Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.29 per share a year ago. These figures are

Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings Miss Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a

Wingstop (WING) Surpasses Q3 Earnings Estimates
Wingstop (WING) Surpasses Q3 Earnings Estimates

Wingstop (WING) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.88 per share a year ago. These figures

Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates
Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates

Verastem (VSTM) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.6 per share a year ago. These figures are

Dave Inc. (DAVE) Q3 Earnings and Revenues Surpass Estimates
Dave Inc. (DAVE) Q3 Earnings and Revenues Surpass Estimates

Dave Inc. (DAVE) came out with quarterly earnings of $4.24 per share, beating the Zacks Consensus Estimate of $2.29 per share. This compares to earnings of $1.51 per share a year ago. These figures

Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?
Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock?

Solventum SOLV is scheduled to release third-quarter 2025 results on Nov. 6, after market close. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 16.55%

ETFs in Spotlight as Coinbase Shares Slip Despite Upbeat Q3 Earnings: https://staticx-tuner.zacks.com/images/articles/main/3d/115667.jpg
ETFs in Spotlight as Coinbase Shares Slip Despite Upbeat Q3 Earnings

Shares of Coinbase Global, Inc. (COIN) gained 4.6% on Oct. 31, following the company’s better-than-expected third-quarter 2025 results, backed by solid trading volume. However, the stock failed to

DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?
DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock?

DENTSPLY SIRONA Inc. XRAY is scheduled to release third-quarter 2025 results on Nov. 6, before the opening bell.

In the last reported quarter, the company’s earnings beat the Zacks Consensus

Will Strong Segmental Performance Drive MCK's Top Line in Q2?
Will Strong Segmental Performance Drive MCK's Top Line in Q2?

McKesson Corporation MCK is scheduled to report second-quarter fiscal 2026 results on Nov. 5, after market close.

The company delivered an earnings surprise of 0.36% in the last reported quarter

Sunrun to Release Q3 Earnings: What's in Store for the Stock?
Sunrun to Release Q3 Earnings: What's in Store for the Stock?

Sunrun Inc. RUN is scheduled to release third-quarter 2025 results on Nov. 6, after market close. The company delivered an earnings surprise of 694.4% in the last reported quarter. Let’s discuss the

HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline

Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025.

Total revenues comprise product sales and royalty, contract and other revenues.

While

Should You Buy Moderna Stock Ahead of Q3 Earnings Report?
Should You Buy Moderna Stock Ahead of Q3 Earnings Report?

Moderna MRNA is set to report third-quarter 2025 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $860 million and a loss of $2.15 per

Xometry (XMTR) Q3 Earnings Match Estimates
Xometry (XMTR) Q3 Earnings Match Estimates

Xometry (XMTR) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.02 per share a year ago. These figures are adjusted

Vital Farms (VITL) Q3 Earnings and Revenues Surpass Estimates
Vital Farms (VITL) Q3 Earnings and Revenues Surpass Estimates

Vital Farms (VITL) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.16 per share a year ago. These figures

Chicago Atlantic Real Estate Finance, Inc. (REFI) Tops Q3 Earnings and Revenue Estimates
Chicago Atlantic Real Estate Finance, Inc. (REFI) Tops Q3 Earnings and Revenue Estimates

Chicago Atlantic Real Estate Finance, Inc. (REFI) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.46 per share. This compares to earnings of $0.56 per

Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.1 per share a year ago. These

Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago. These

Knife River (KNF) Q3 Earnings and Revenues Surpass Estimates
Knife River (KNF) Q3 Earnings and Revenues Surpass Estimates

Knife River (KNF) came out with quarterly earnings of $2.52 per share, beating the Zacks Consensus Estimate of $2.45 per share. This compares to earnings of $2.6 per share a year ago. These figures